H4 Orphan Pharma and TheraVet join forces to accelerate the development of an innovative treatment for pulmonary fibrosis

H4 Orphan is pleased to announce a strategic agreement between TheraVet and H4 Orphan Pharma whereby H4 Orphan Pharma’s lead clinical programme in idiopathic pulmonary fibrosis is contributed to TheraVet